NCT01371201View on ClinicalTrials.gov

First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

December 22, 2011

Primary Completion Date

October 1, 2013

Study Completion Date

April 20, 2021

Conditions
Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Interventions
DRUG

Sunitinib

sunitinib 37.5 mg per day

DRUG

Placebo

Placebo 37.5 mg per day

Trial Locations (4)

6525

Radboud University Nijmegen Medical Centre, Nijmegen

35128

University of Padova, Padua

94805

Institut de Cancérologie Gustave roussy, Villejuif

97080

Universitätsklinikum Würzburg, Würburg

All Listed Sponsors
collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

European Network for the Study of Adrenal Tumours

UNKNOWN

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT01371201 - First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma | Biotech Hunter | Biotech Hunter